Welcome to our dedicated page for Rigel Pharmaceuticals news (Ticker: RIGL), a resource for investors and traders seeking the latest updates and insights on Rigel Pharmaceuticals stock.
Rigel Pharmaceuticals reports news on a commercial-stage biotechnology business focused on hematologic disorders and cancer. Company updates commonly cover sales of TAVALISSE (fostamatinib disodium hexahydrate), GAVRETO (pralsetinib) and REZLIDHIA (olutasidenib), along with contract revenue from collaborations and quarterly operating results.
Recurring developments also include clinical and regulatory updates for Rigel's pipeline, including R289 in lower-risk MDS, published clinical data involving GAVRETO, licensing and collaboration activity, board appointments, equity inducement grants and other governance matters tied to its Nasdaq-listed common stock.
Rigel Pharmaceuticals (RIGL) will participate in three investor conferences in New York in September 2026, featuring its chief financial officer, Dean Schorno. The company will join Citi's 2026 Biopharma Back to School Conference for one-on-one meetings on September 9. It will hold one-on-one meetings and present a company overview at the Cantor Global Healthcare Conference 2026 on September 10 at 11:30 a.m. ET, and at the H.C. Wainwright 28th Annual Global Investment Conference on September 15 at 10:00 a.m. ET. Live and archived webcasts for the Cantor and H.C. Wainwright presentations will be available via the Investor Relations section of www.rigel.com.
Rigel (Nasdaq: RIGL) announced that VEPPANU™ (vepdegestrant), an oral PROteolysis TArgeting Chimera (PROTAC), is now commercially available by prescription in the United States and Puerto Rico. The drug is indicated for adults with ER+/HER2-, ESR1‑mutated advanced or metastatic breast cancer whose disease has progressed after at least one line of endocrine therapy, based on an FDA‑authorized test.
According to Rigel, VEPPANU is the first and only FDA‑approved PROTAC and showed statistically significant, clinically meaningful progression‑free survival improvement versus fulvestrant in a pivotal trial. The recommended dose is 200 mg once daily, priced at $29,400 per 30‑day supply, distributed through specialty distributors and pharmacies. Rigel supports access via its RIGEL ONECARE® patient assistance and reimbursement services and holds an exclusive global license to develop, manufacture and commercialize VEPPANU from Arvinas and Pfizer. The label includes warnings for QTc interval prolongation, embryo‑fetal toxicity, and details on adverse reactions, drug interactions and contraception and lactation guidance.
Rigel (Nasdaq:RIGL) reported second quarter 2026 total revenues of $78.7 million, including net product sales of $67.0 million and collaboration revenues of $11.7 million, and net income of $17.3 million ($0.88 diluted EPS). TAVALISSE sales rose 18% to $47.4 million, REZLIDHIA grew 27% to $8.9 million, while GAVRETO declined 10% to $10.7 million.
Rigel entered an exclusive global license with Arvinas and Pfizer for VEPPANU (vepdegestrant), paying a $70.0 million upfront fee and expecting U.S. commercial availability in mid-August 2026. The R289 Phase 1b MDS study remains on track to complete dose-expansion enrollment and select a Phase 2 dose in second-half 2026.
For the first half of 2026, total revenues reached $137.5 million with net product sales up 19% year over year to $121.9 million. Rigel raised its 2026 revenue outlook to $285–$295 million and continues to expect positive full-year net income, excluding any contribution from VEPPANU.
Rigel Pharmaceuticals (Nasdaq: RIGL) will report its second quarter 2026 financial results after market close on Tuesday, August 4, 2026, followed by a live conference call and webcast at 4:30 p.m. ET (1:30 p.m. PT) led by senior management.
Investors can join by dialing 877-407-3088 (domestic) or 201-389-0927 (international), or via the webcast in the Investor Relations section of www.rigel.com, where a replay will be available for 90 days.
Rigel Pharmaceuticals (Nasdaq:RIGL) granted equity awards under its Inducement Plan, approved by the board’s Compensation Committee and made under NASDAQ Listing Rule 5635(c)(4).
The company granted 13,375 restricted stock units to six new non-executive employees, vesting over four years with 25% vesting each year.
Rigel (Nasdaq:RIGL) appointed board member Alison L. Hannah, M.D. as Executive Vice President and Chief Medical Officer, effective July 1, 2026, succeeding Lisa Rojkjaer, M.D.
Rigel highlighted Dr. Hannah’s extensive oncology development background and provided updated timelines for its Phase 1b R289 program in lower-risk MDS.
Rigel (Nasdaq:RIGL) closed its exclusive global license agreement with Arvinas and Pfizer for VEPPANU™ (vepdegestrant), effective June 11, 2026. Rigel paid a $70 million upfront, split evenly between Arvinas and Pfizer, and expects VEPPANU to be commercially available in August.
VEPPANU is FDA-approved for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after at least one endocrine therapy. Key safety considerations include QTc prolongation, embryo-fetal toxicity, serious adverse reactions in 9% of patients, and fatal reactions in 1%.
Rigel (Nasdaq:RIGL) announced that president and CEO Raul Rodriguez will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 8:45 a.m. ET in New York.
Investors can access a live webcast and archived replay via Rigel's investor relations website.
Rigel (Nasdaq:RIGL) will present new data on GAVRETO (pralsetinib), REZLIDHIA (olutasidenib), and TAVALISSE (fostamatinib) at the 2026 ASCO Annual Meeting and EHA2026 Congress. Highlights include Phase 3 AcceleRET-Lung final results, ARROW thyroid cancer data, and real-world outcomes for mIDH1 AML after venetoclax.
Rigel (Nasdaq:RIGL) announced that CFO Dean Schorno will present a company overview at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, at 9:30 a.m. ET in New York.
A live webcast and archived replay will be available via Rigel’s Investor Relations website.